Gus Halas Net Worth

The estimated Net Worth of Gus D Halas is at least $744 Тысяча dollars as of 5 June 2024. Mr. Halas owns over 10,061 units of OptimizeRx Corp stock worth over $589,141 and over the last 14 years he sold OPRX stock worth over $0. In addition, he makes $155,348 as Chairman of the Board at OptimizeRx Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Halas OPRX stock SEC Form 4 insiders trading

Gus has made over 9 trades of the OptimizeRx Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 10,061 units of OPRX stock worth $73,244 on 5 June 2024.

The largest trade he's ever made was buying 21,990 units of OptimizeRx Corp stock on 20 March 2017 worth over $16,932. On average, Gus trades about 1,198 units every 62 days since 2011. As of 5 June 2024 he still owns at least 80,926 units of OptimizeRx Corp stock.

You can see the complete history of Mr. Halas stock trades at the bottom of the page.

Gus Halas biography

Gus D. Halas serves as Chairman of the Board of the Company. He was Chief Executive Officer and President of the Central Operating Companies at Central Garden & Pet Company from April 2011 through May 2013 and currently serves as a consultant to that Company. Mr. Halas was President and Chief Executive Officer of T-3 Energy Services, Inc. from May 2003 to March 2009 and also served as Chairman of the Board of Directors from March 2004 to March 2009. From August 2001 to April 2003, Mr. Halas served as President and Chief Executive Officer of Clore Automotive, Inc. He also serves as a director for Triangle Petroleum Corp., Hooper Holmes, Inc., School Specialty, Inc., and Madelena Energy. Aside from that provided above, Mr. Halas does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940.

What is the salary of Gus Halas?

As the Chairman of the Board of OptimizeRx Corp, the total compensation of Gus Halas at OptimizeRx Corp is $155,348. There are 6 executives at OptimizeRx Corp getting paid more, with Stephen Silvestro having the highest compensation of $1,210,200.

How old is Gus Halas?

Gus Halas is 69, he's been the Chairman of the Board of OptimizeRx Corp since 2017. There are no older and 13 younger executives at OptimizeRx Corp.

What's Gus Halas's mailing address?

Gus's mailing address filed with the SEC is C/O OPTIMIZERX CORPORATION, 260 CHARLES STREET, SUITE 302, WALTHAM, MA, 02453.

Insiders trading at OptimizeRx Corp

Over the last 2001 years, insiders at OptimizeRx Corp have traded over $20,012,815 worth of OptimizeRx Corp stock and bought 258,753 units worth $1,128,145 . The most active insiders traders include Investment Company, Inc. Awm, Bradley Louis Radoff и David Harrell. On average, OptimizeRx Corp executives and independent directors trade stock every 32 days with the average trade being worth of $183,485. The most recent stock trade was executed by Patrick D Spangler on 5 June 2024, trading 10,061 units of OPRX stock currently worth $73,244.

What does OptimizeRx Corp do?

optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.

Complete history of Mr. Halas stock trades at Central Garden & Pet Co, Central Garden & Pet Co и OptimizeRx Corp

OptimizeRx Corp executives and stock owners

OptimizeRx Corp executives and other stock owners filed with the SEC include:

• Stephen Silvestro,
  Chief Commercial Officer
• William Febbo,
  Chief Executive Officer, Director
• William J. Febbo,
  CEO & Director
• Stephen L. Silvestro,
  Chief Commercial Officer
• Miriam Paramore,
  President
• Douglas Baker,
  Chief Financial Officer
• Gus Halas,
  Chairman of the Board
• Lynn Vos,
  Independent Director
• Patrick Spangler,
  Independent Director
• James Lang,
  Independent Director
• Angelo Campano,
  Senior Vice President - Principal of Agency Channels
• Ron Both,
  Investor Relations
• Gregory Wasson,
  Director
• Todd Inman,
  Chief Technology Officer
• Maira Alejandra,
  Media Relations Mang.
• Todd Inman,
  Chief Technology Officer
• Andrew Jacob D'Silva,
  Sr. VP of Corp. Fin.
• Douglas P. Baker,
  Exec. VP of Fin. & Accounting
• Edward Stelmakh C.M.A., M.B.A., MBA,
  CFO & COO
• Rebecca Whitney,
  Sr. VP of Commercial Operations
• Terence J. Hamilton,
  Sr. VP of Pharma
• Sheryl Kearney,
  HR Mang.
• Marion K Odence-Ford,
  Gen. Counsel & Chief Compliance Officer
• Cathy Klema,
  Director
• Ellen O'connor Vos,
  Director
• Plc Wpp Luxembourg Gamma Th...,
  
• Investment Company, Inc. Awm,
  10% owner
• Bradley Louis Radoff,
  10% owner
• Jack T Pinney,
  Director
• Richard Kraniak,
  10% owner
• David Lester,
  Chairman of the Board
• David Harrell,
  Chief Executive Officer
• Terrence Hamilton,
  Vice President
• James M Brooks,
  SVP of Business Development
• Brian J Dillon,
  SR. VP OF PRODUCT & STRATEGY
• Brian Clark Mc Carthy,
  Chief Revenue Officer
• Marion Odence Ford,
  General Counsel and CCO
• Edward Stelmakh,
  CFO/COO
• Doug Besch,
  Chief Product Officer
• Theresa Greco,
  Chief Commercial Officer